Modality
ERT
MOA
CD47i
Target
TROP-2
Pathway
DDR
DMD
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
~Nov 2019
→ ~Feb 2021
Phase 2
May 2021
→ Mar 2031
Phase 2Current
NCT04793115
1,512 pts·DMD
2021-05→2031-03·Terminated
1,512 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-03-044.9y awayPh3 Readout· DMD
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2/3
Termina…
Catalysts
Ph3 Readout
2031-03-04 · 4.9y away
DMD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04793115 | Phase 2/3 | DMD | Terminated | 1512 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |